Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides

Anti-Cancer Drug Design

Volumn 12, Issue 5, 1997, Pages 383-393

  Geary, Richard S ^a   Leeds, Janet M ^a   Henry, Scott P ^a   Monteith, David K ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; INTERCELLULAR ADHESION MOLECULE 1; ISIS 3521; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN P53; RAF PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER; CLINICAL TRIAL; DNA SEQUENCE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG UPTAKE; GENE TARGETING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; SPECIES SPECIFICITY; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0030797704     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. AGRAWAL, S., RUSTAGI, PK. & SHAW, D.R. (1995a). Novel enzymatic and immunological responses to oligonucleotides. Toxicology Letters, 82-3, 431.
2. AGRAWAL, S, TEMSAMANI J., GALBRAITH, W. & TANG, J. (1995b). Pharmacoketics of antisense oligonucleotides. Drug Disposition, 28, 7.
3. AGRAWAL, S, TEMSAMANI, J & TANG, J.Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proceedings of the National Academy of Sciences of the United States of America, 88, 7595.
4. BASU, A (1993). The potential of protein kinase C as a target for anticancer treatment. Pharmacology and Therapeutics, 59, 257.
5. BOS, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Research, 49, 4682.
6. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. Journal of Pharmacology and Experimental Therapeutics, 267, 1181.
7. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. Journal of Pharmacology and Experimental Therapeutics, 269, 89.
8. CROOKE, S.T. (1995). Progress in antisense therapeutics. Hematologic Pathology, 9, 59.
9. CROOKE, S.T. (1996). Therapeutic applications of oligonucleotides in medicine. Chemistry and Industry, 90.
10. GLOVER, J.M., LEEDS, J.M., MANT, T.G.K., AMIN, D., KISNER, D.L., ZUCKERMAN, J., LEVIN, A.A. & SHANAHAN, W.R. (1997). Phase 1 safety and pharmacokinetic profile of an ICAM-I antisense oligodeoxynucleotide (ISIS 2302). Submitted.
11. HENRY, S.P., LARKIN, R., NOVOTNY, W.F. & KORNBRUST, D.J. (1994). Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharmaceutical Research, 11, S.
12. HENRY, S.P., GICLAS, P.C., LEEDS, J., PANGBURN, M., HOBSON, W.C. &. KORNBRUST, D.J. (1997a). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of activation. Journal of Pharmacology and Experimental Therapeutics, 281, 810.
13. HENRY, S.P., MONTEITH, D. & LEVIN, A.A. (1997b). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design, 12, 395.
14. LEEDS, J.M., GRAHAM, M.J., TRUONG, L. & CUMMINS, L.L. (1996). Quantitation of phosphorothioate oligonucleotides in human plasma. Analytical Biochemistry, 235, 36.
15. PIERGA, J.-Y. & MAGDELENAT, H. (1994). Applications of antisense oligonucleotides in oncology. Cellular and Molecular Biology, 40, 237.
16. RIFAI, A., BYRSCH, W., FADDEN, K., CLARK, J. & SCHLINGENSIPEN, K.-H. (1996). Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. American Journal of Pathology, 149, 717.
17. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and phosphorothioate. Molecular Pharmacology, 45, 932.
18. SRINIVASAN, S.K. & IVERSEN, p. (1995). Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Journal of Clinical Laboratory Analysis, 9, 129.
19. TAKAKURA, Y., MAHATO, R I., YOSHIDA, M , KANAMARU, T & HASHIDA, M. (1996). Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug D, 6, 177.
20. WHITFIELD, L.R. & PEGG, D G. (1993) In Toxicokinetics of Anticancer Compounds. Welling, P.G. (ed.), p. 276. Marcel Dekker: Ann Arbor, MI.
21. ZHANG. R., DIASIO, R.B., LU, Z, LIU, T., JIANG, Z., GALBRAITH, W.M & AGRAWAL, S. (1995a). Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent virus type-1. Biochemical Pharmacology, 49, 929.
22. ZHANG, R., YAN, J., SHAHINIAN, H., AMIN, G., LU, Z., LIU, T., SAAG, M.S., JIANG, Z., TEMSAMANI, J., MARTIN, R, SCHECHTER, P.J, AGRAWAL, S & DLASIO, R.B. (1995b). Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clinical Pharmacology and Therapeutics, 45.
23. ZHANG, R.W., IYER, R.P., YU, D., TAN, W.T., ZHANG, X S., LU, Z.H., ZHAO, H. & AGRAWAL, S. (1996). Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. Journal of Pharmacology and Experimental Therapeutics, 278, 971.